Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)

The Journal of Pharmacology and Experimental Therapeutics
Matthew J FellD D Schoepp

Abstract

(-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039) is a potent and selective group II metabotropic glutamate [(mGlu)2 and mGlu3] receptor agonist for which its prodrug LY2140023 [(1R,4S,5S,6S)-2-thiabicyclo[3.1.0]-hexane-4,6-dicarboxylic acid,4-[(2S)-2-amino-4-(methylthio)-1-oxobutyl]amino-, 2,2-dioxide monohydrate] has recently been shown to have efficacy in the treatment of the positive and negative symptoms of schizophrenia. In this article, we use mGlu receptor-deficient mice to investigate the relative contribution of mGlu2 and mGlu3 receptors in mediating the antipsychotic profile of LY404039 in the phencyclidine (PCP) and d-amphetamine (AMP) models of psychosis. To further explore the mechanism of action of LY404039, we compared the drugs' ability to block PCP-induced hyperlocomotion to that of atypical antipsychotics in wild-type and mice lacking mGlu2/3 receptors. In wild-type animals, LY404039 (3-30 mg/kg i.p.) significantly reversed AMP (5 mg/kg, i.p.)-induced increases in ambulations, distance traveled, and reduced time spent at rest. LY404039 reversed PCP (7.5 mg/kg i.p.)-evoked behaviors at 10 mg/kg. The antipsychotic-like effects of LY404039 (10 mg/kg i.p.) on PCP and AMP-ev...Continue Reading

References

Aug 27, 2009·Cellular and Molecular Life Sciences : CMLS·José L MorenoJavier González-Maeso
Jan 5, 2011·Psychopharmacology·Katrine FabriciusBjörn Steiniger-Brach
Mar 5, 2013·European Archives of Psychiatry and Clinical Neuroscience·Kenji HashimotoAndrea Schmitt
Feb 23, 2012·Journal of Medicinal Chemistry·Andrés A TrabancoJosé María Cid
Aug 7, 2012·Nature Neuroscience·Mitsumasa KuritaJavier González-Maeso
Feb 18, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Dong XiWen-Jun Gao
Jan 1, 2009·Nature Reviews. Drug Discovery·P Jeffrey ConnCraig W Lindsley
Jul 13, 2011·Schizophrenia Bulletin·Anouk MarsmanHilleke E Hulshoff Pol
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·Colleen M Niswender, P Jeffrey Conn
Feb 4, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·José L MorenoJavier González-Maeso
Jul 26, 2012·ISRN Pharmacology·Kyra-Verena SendtDerek K Tracy
Feb 25, 2014·Pharmacology & Therapeutics·Catherine L WinchesterBrian J Morris
May 18, 2011·Evidence-based Complementary and Alternative Medicine : ECAM·Lisa M Del Valle-MojicaJosé G Ortiz
Feb 19, 2015·Pharmacology Research & Perspectives·Hilde LavreysenJosé María Cid Nuñez
Jan 19, 2016·Pflügers Archiv : European journal of physiology·Lia BakiDiomedes E Logothetis
Mar 18, 2016·ACS Medicinal Chemistry Letters·Joseph E PeroMarlene A Jacobson
Oct 1, 2011·Trends in Molecular Medicine·Julie R FieldP Jeffrey Conn
Oct 12, 2010·Current Opinion in Neurobiology·Nicholas J BrayAndreas Meyer-Lindenberg
Jan 12, 2010·Neuroscience and Biobehavioral Reviews·Suat Ying Tan CherlynKang Sim
Aug 26, 2009·Pharmacology, Biochemistry, and Behavior·Rayna M BauzoLeonard L Howell
Mar 10, 2009·Trends in Neurosciences·Javier González-Maeso, Stuart C Sealfon
Dec 9, 2008·Trends in Pharmacological Sciences·P Jeffrey ConnCarrie K Jones
Jan 24, 2015·Neuroscience and Biobehavioral Reviews·Colm M O'Tuathaigh, John L Waddington
Feb 19, 2015·Pharmacology Research & Perspectives·Hilde LavreysenAnton Megens

Citations

Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jan 1, 1993·Schizophrenia Bulletin·N C Andreasen, W T Carpenter
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·P Jeffrey Conn, J P Pin
Mar 17, 2000·Brain Research. Brain Research Reviews·George K Aghajanian, Gerard J Marek
Aug 11, 2000·Journal of Neurochemistry·J Cartmell, D D Schoepp
Sep 16, 2000·European Journal of Pharmacology·J CartmellD D Schoepp
Oct 12, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J C Gewirtz, Gerard J Marek
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mark A Geyer, Bart Ellenbroek
Aug 18, 2004·Proceedings of the National Academy of Sciences of the United States of America·Michael F EganDaniel R Weinberger
Jan 25, 2005·Nature Reviews. Drug Discovery·Chad J SwansonD D Schoepp
Oct 15, 2005·The Journal of Pharmacology and Experimental Therapeutics·Linda M Rorick-KehnDavid L McKinzie
Oct 4, 2006·Neuron·Christopher A RossJoseph T Coyle
May 29, 2007·Biological Psychiatry·Corrado CortiFrancesco Ferraguti

Related Concepts

Metabotropic glutamate receptors type 3
LY 404039
Antipsychotic Effect
Atypical Antipsychotic [EPC]
n-hexane
LY 2140023
Schizophrenia
Clozapine
Receptors, Metabotropic Glutamate
GRM3 gene

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here